AlzChem Group Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Andreas Niedermaier
Algemeen directeur
€1.5m
Totale compensatie
| Percentage CEO-salaris | 20.9% |
| Dienstverband CEO | 13.1yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 7yrs |
| Gemiddelde ambtstermijn bestuur | 11.5yrs |
Recente managementupdates
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05Recent updates
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €46m |
| Mar 31 2024 | n/a | n/a | €39m |
| Dec 31 2023 | €2m | €315k | €35m |
| Sep 30 2023 | n/a | n/a | €30m |
| Jun 30 2023 | n/a | n/a | €28m |
| Mar 31 2023 | n/a | n/a | €30m |
| Dec 31 2022 | €818k | €315k | €30m |
| Sep 30 2022 | n/a | n/a | €29m |
| Jun 30 2022 | n/a | n/a | €28m |
| Mar 31 2022 | n/a | n/a | €27m |
| Dec 31 2021 | €890k | €300k | €28m |
| Sep 30 2021 | n/a | n/a | €27m |
| Jun 30 2021 | n/a | n/a | €26m |
| Mar 31 2021 | n/a | n/a | €23m |
| Dec 31 2020 | €786k | €300k | €20m |
| Sep 30 2020 | n/a | n/a | €16m |
| Jun 30 2020 | n/a | n/a | €17m |
| Mar 31 2020 | n/a | n/a | €17m |
| Dec 31 2019 | €915k | €260k | €18m |
| Sep 30 2019 | n/a | n/a | €19m |
| Jun 30 2019 | n/a | n/a | €18m |
| Mar 31 2019 | n/a | n/a | €20m |
| Dec 31 2018 | n/a | n/a | €23m |
| Sep 30 2018 | n/a | n/a | €22m |
| Jun 30 2018 | €453k | €110k | €32m |
| Mar 31 2018 | n/a | n/a | €21m |
| Dec 31 2017 | €1m | €220k | €20m |
Compensatie versus markt: De totale vergoeding ($USD 1.64M ) Andreas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.08M ).
Compensatie versus inkomsten: De vergoeding van Andreas is het afgelopen jaar met meer dan 20% gestegen.
CEO
Andreas Niedermaier (55 yo)
13.1yrs
Tenure
€1,509,000
Compensatie
Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of Executive Board | 13.1yrs | €1.51m | geen gegevens | |
| Member of Executive Board & COO | 8.8yrs | €1.24m | geen gegevens | |
| Chief Sales Officer & Member of Executive Board | 5.3yrs | €1.24m | geen gegevens | |
| CFO & Member of Management Board | less than a year | geen gegevens | geen gegevens |
7.0yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ACT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Supervisory Board | 15.1yrs | €42.00k | geen gegevens | |
| Independent Member of the Supervisory Board | 8yrs | €24.00k | geen gegevens | |
| Deputy Chairman of the Supervisory Board | 8yrs | €32.00k | geen gegevens | |
| Member of the Supervisory Board | 15.1yrs | €22.00k | geen gegevens |
11.5yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ACT zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.5 jaar).